Breast Cancer

Debu Tripathy, MD, discusses the emergence of genomics research in breast cancer.

CDK4/6 inhibitors in the metastatic setting have demonstrated clinical benefit in the hormone receptor–positive breast cancer population, leading to curiosity of its activity in early-stage patients and setting the stage for a handful of informative clinical trials.

Immunotherapy treatment for early-stage triple-negative breast cancer is enjoying a boom period, though there are still unanswered questions, particularly around the optimal chemotherapy backbone and patient selection.

Getting a start in clinical research can appear daunting, said Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C). Fortunately, all it really takes is a question and a bit of drive.

Pat W. Whitworth, MD, explains how data from past studies are informing the use of circulating tumor DNA and talks about the potential of these assays to guide treatment decisions in patients with breast cancer.

Charles L. Loprinzi, MD, discusses some of the most common treatment-related toxicities in breast cancer and provided insight into various current and investigational approaches available to patients.

Patients with newly diagnosed metastatic triple-negative breast cancer should undergo PD-L1 expression testing on tumors to determine whether they are candidates for frontline chemoimmunotherapy.

Treatment with eribulin elicited an estimated 2-year overall survival rate of 53.6% for patients with metastatic breast cancer previously treated with atezolizumab or sacituzumab govitecan, according to real-world findings.

Sara A. Hurvitz, MD, discusses utilizing CDK4/6 inhibitors in hormone receptor-positive breast cancer.

Sara M. Tolaney, MD, MPH, discusses the efficacy of trastuzumab deruxtecan in the second-line setting and its potential to move into the first-line treatment of HER2-positive breast cancer.

The 39th Annual Miami Breast Cancer Conference® makes its return to the Fontainebleau Miami Beach in Florida with a twist on both the agenda and the setting.

A panel of experts briefly reviews the treatment options available for patients with ER+, HER2+ metastatic breast cancer.

Expert panelists discuss the optimal management patients with special subsets of HER2+ metastatic breast cancer, such as HR+ or HER2-low disease.

Tiffany A. Traina, MD, discusses the implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Jonathan Chernoff, MD, PhD, Cancer Center Director at Fox Chase Cancer Center, was recently awarded a $50,000 grant from the Pennsylvania Breast Cancer Coalition.

From early phase 1/2 to pivotal phase 3 data, the 2021 San Antonio Breast Cancer Symposium was full of exciting research with selective estrogen receptor degraders, CDK4/6 inhibitors, and antibody-drug conjugates.

Shared insight on the potential role for surgery in the setting of HER2+ metastatic breast cancer in the context of pharmacologic therapy.

Rounding out their conversation on SABCS 2021, experts discuss small molecule–based treatment strategies for relapsed/refractory HER2+ metastatic breast cancer.

Individuals with Li-Fraumeni Syndrome, a rare hereditary condition, are at increased risk for a wide spectrum of malignancies, including breast cancer and sarcomas. Investigators are working to determine whether metformin, a drug indicated for diabetes and infertility caused by polycystic ovarian syndrome, can prevent cancers in LFS carriers.

Yara Abdou, MD, discusses the significance of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Neil M. Iyengar, MD, discusses the use of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

Trastuzumab deruxtecan resulted in a statistically significant improvement in progression-free survival and overall survival compared with physician’s choice of chemotherapy in patients with HER2-low unresectable and/or metastatic breast cancer, irrespective of hormone receptor status, meeting the primary and secondary end points of the phase 3 DESTINY-Breast 04 trial.

Joyce A. O’Shaughnessy, MD, the 2016 Giant of Cancer Care® for Community Outreach/Education, explains her continued commitment to impacting change in the space and aiding other oncologists.

Androgen recepter positivity serves as an independent predictor of beneficial outcomes in breast cancer.